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What this study adds: Polymorphisms within the LRP1 gene have been suggested to 24 
contribute to AAA risk. This study demonstrates that plasma concentrations of LRP1 are 25 
similar in men with and without AAA suggesting that this protein is an unsuitable marker to 26 
screen at-risk populations. This study confirms that that LRP1 expression is reduced in aortic 27 
biopsies collected from AAA patients compared to non-aneurysmal controls and 28 
demonstrates that LRP1 inhibition reduces the ability of vascular smooth muscle cells to 29 
internalise matrix metalloprotease 9 in vitro. These findings suggest that localised LRP1 30 
dysregulation may be important in AAA pathogenesis, but is an unsuitable marker with 31 
which to screen at-risk populations. 32 
33 
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Objectives: Recent genetic data suggest that a polymorphism of the low density lipoprotein 35 
receptor-related protein 1 (LRP1) gene is an independent risk factor for abdominal aortic 36 
aneurysm. The aims of this study were to assess whether plasma and aortic concentrations of 37 
LRP1 were associated with abdominal aortic aneurysm, and to investigate the possible 38 
relevance of LRP1 to abdominal aortic aneurysm pathophysiology. 39 
Design, Materials and Methods: Three analyses were conducted. Initially, plasma LRP1 40 
concentrations were measured in community dwelling men with and without abdominal 41 
aortic aneurysm (n=189 and 309 respectively) using ELISA. Secondly, Western blotting 42 
analyses were employed to compare the expression of LRP1 protein in aortic biopsies 43 
collected from abdominal aortic aneurysm patients and non-aneurysmal post-mortem donors 44 
(n=6/group). Finally, the effect of in vitro LRP1 blockade on MMP9 clearance by vascular 45 
smooth muscle cells was assessed by zymography.  46 
Results: Plasma LRP1 concentrations did not differ between groups of men with and without 47 
abdominal aortic aneurysm (median concentration 4.56 µg/mL (IQR 3.39-5.96) and 4.43 48 
µg/mL (IQR 3.44-5.84); P=0.48), and were not associated with abdominal aortic aneurysm 49 
after adjusting for other risk factors (odds ratio: 1.10 (95% confidence interval: 0.91-1.32); 50 
P=0.35). In contrast, LRP1 expression was ~3.4 fold lower in aortic biopsies recovered from 51 
abdominal aortic aneurysm patients compared to controls (median (IQR) expression 1.72 52 
(0.94-3.14) and 5.91 (4.63-6.94) relative density units; P=0.004). In vitro LRP1 blockade 53 
significantly reduced the ability of vascular smooth muscle cells to internalise  extracellular 54 
MMP9. 55 
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Conclusions: These data suggest that aortic but not circulating LRP1 is down-regulated in 56 
abdominal aortic aneurysm patients, and indicates a possible role for this protein in clearing 57 
an aneurysm-relevant ligand. 58 
Key words: Abdominal aortic aneurysm; Low density lipoprotein receptor related protein-1; 59 
biomarker; matrix metalloprotease 9. 60 
61 
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Abdominal aortic aneurysm (AAA) affects ~2% men and ~1% of women aged >65 years, and 63 
significantly increases the risk of mortality through aortic rupture and associated 64 
cardiovascular events.1, 2 The aetiology of AAA remains unclear, however, inflammation, 65 
extracellular matrix degeneration and vascular smooth muscle cell (VSMC) loss appear to be 66 
important in the pathogenesis.3, 4 AAA risk factors include advanced age, male sex and 67 
smoking.1 A positive family history increases AAA risk ~2-fold, suggesting that genetic 68 
factors are important in AAA development.5, 6 A genome-wide association study (GWAS) 69 
identified a positive association of the rs1466535  major (C) allele within the low-density 70 
lipoprotein receptor-related protein 1 (LRP1) gene with AAA presence (odds ratio ~1.2).7 71 
This association appeared AAA specific and was maintained after adjusting for 72 
cardiovascular risk factors leading to the suggestion that the LRP1 rs1466535 C allele might 73 
significantly contribute to AAA risk.8, 9 This is contradicted, however by recent data reporting 74 
a positive association between AAA and the LRP1 rs1466535 T (minor) allele in a  75 
geographically distinct patient population.10  76 
 77 
LRP1 is structurally related to the low density lipoprotein receptor and comprises a 100 78 
amino acid cytoplasmic domain, a membrane spanning region, and an extracellular loop with 79 
4 ligand binding regions.11, 12 LRP1 is predominantly expressed by VSMCs and facilitates the 80 
internalisation and clearance of bound ligands.12-14 Previous studies suggest that LRP1 has 81 
functions beyond lipid metabolism and known LRP1 ligands include growth factors, matrix 82 
metalloproteases (MMPs), protease-inhibitor complexes and extracellular matrix 83 
components.8, 11, 12 Conditional LRP1 knockout rodent models demonstrate that LRP1 84 
deficiency results in abnormal VSMC proliferation and migration, increased extracellular 85 
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matrix turnover and aneurysm formation within the mesenteric arteries. 14-16 Currently, only 86 
one study has directly investigated whether LRP1 expression is altered in human AAA.17 In 87 
this study Chan et al. employed Western blotting and immunohistochemistry to demonstrate 88 
significant down-regulation of the LRP1 protein in aortic biopsies of Chinese AAA patients 89 
compared to non-aneurysmal controls. We hypothesised that reduced aortic LRP1 90 
concentrations may result from release of this protein from the aneurysm wall, which may 91 
increase circulating LRP1 concentrations in AAA patients. Here, we assess plasma LRP1 as a 92 
potential AAA biomarker, confirm that aortic expression of LRP1 is significantly lower in 93 
AAA biopsies compared to controls, and suggest that this protein may play a role in clearing 94 
MMP9 from the aortic wall.  95 
96 
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Materials and methods 97 
 98 
Detailed materials and methods are provided in Supplementary File 1. 99 
 100 
Participants: Samples collected from 3 Australian cohorts were used: 1) plasma samples 101 
collected from participants of the Health In Men Study (HIMS); 2) aortic biopsies from 102 
patients undergoing open surgery to repair large AAA; 3) aortic biopsies from non-103 
aneurysmal heart beating brain dead organ donors.18 The cohort characteristics and protocols 104 
of the HIMS have been previously reported.18 For HIMS participants, an infra-renal aortic 105 
(IRA) diameter of 30-55 mm was defined as a small AAA; and IRA diameters >55 mm were 106 
considered large AAAs. Clinical information collected during the HIMS included age, 107 
medical history and smoking status. For patients undergoing AAA repair, risk factors were 108 
recorded as previously described (Supplementary File 1).19, 20 Maximum IRA diameter was 109 
measured from axial computed tomography angiography (CTA) images as previously 110 
described.21 No clinical information other than age and sex was available for organ donor 111 
participants. In all instances, written informed consent and institutional ethics approval was 112 
provided.  113 
 114 
Measurement of plasma LRP1: Plasma LRP1 concentrations were measured using a 115 
commercially available ELISA (#E91010Hu, USCN Life Sciences, China). This ELISA 116 
employs antibodies against a soluble extra-cellular LRP1 immunogen suggesting suitability 117 
for plasma analysis. Reported inter and intra-assay variability are <12%. Due to limited 118 
plasma volumes, single measurements were taken for each patient as previously described.19, 119 
22
  120 
 121 
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In vitro experiments: Human aortic VSMC (CC-2571, Lonza) were maintained in growth 123 
medium in a humidified 5% CO2 atmosphere at 37oC and passaged when 70%–80% 124 
confluent. After 5 passages LRP1 blocking antibodies or isotype control antibodies (#MA1-125 
27198 and MA5-14453, respectively, Thermo Fisher Scientific, Australia) were added to the 126 
culture media at concentrations of 30µg/mL. Cell culture supernatants were decanted after 24 127 
hours and replaced with media containing 20ng/mL recombinant human matrix 128 
metalloprotease 9 (MMP9, #911-MP-010, R and D Systems, USA). Cell culture supernatants 129 
were harvested at 24 and 48 hours, and stored at -80oC. Data presented are from 3 130 
independent culture experiments. 131 
 132 
Protein extraction and Western blotting: Isolation of aortic proteins and western blotting was 133 
performed as previously described.23 Full-thickness human abdominal aortic samples were 134 
homogenized in the presence of protease inhibitors. Samples (30 µg protein/lane) were loaded 135 
onto a 10% SDS-polyacrylamide gel, electrophoresed and transferred onto a polyvinylidene 136 
difluoride membrane. The membrane was cut at ~60 kDa and each half separately blocked 137 
with 5% non-fat dry milk at 4ºC overnight. The 60-250 kDa proteins were incubated with 138 
anti-LRP1 antibody (R&D Systems MAB6360, USA), while the proteins <60 kDa were 139 
incubated with anti-β actin antibody, (Abcam, UK #AB75186) for 1 hour (room 140 
temperature). Membranes were washed and incubated with anti-mouse HRP- (LRP1 blot), or 141 
anti-rabbit (β actin)- conjugated IgG (DakoCytomation, Denmark #P0447 and P0448 142 
respectively) for 1 hour (room temperature). Membranes were washed and proteins visualised 143 
with Western Lightning Chemiluminescence Reagent Plus (PerkinElmer Life Sciences, 144 
USA). The relative density of the LRP1 band was standardised by dividing by mean beta-145 
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actin density for the respective experimental group. Reported data refer to standardised LRP1 146 
expression. 147 
 148 
Gelatin zymography: Five µL of VSMC culture supernatant was loaded onto a 10% 149 
polyacrylamide gel containing 1 mg/mL gelatin. Samples were electrophoresed and washed 150 
twice in 2.5% (v/v) Triton X 100. Gels were incubated overnight in 50mM Tris-HCl (pH 151 
8.0), 5mM CaCl2 at 37oC and stained in 0.5% (w/v) Coomassie Blue R-250 for 30 mins. Gels 152 
were destained with 40% (v/v) methanol, 10% (v/v) acetic acid, 50% (v/v) water, to visualise 153 
protease activity and analysed via densitometry as above. 154 
 155 
Statistical analyses: Data were analysed using SPSS v.21 (IBM) and Prism v.6 (GraphPad 156 
Software Inc, San Diego, USA). Continuous variables were analysed using the Mann-157 
Whitney U test. Nominal variables were assessed using the chi-squared test. Correlations 158 
were assessed using Spearman Rho analyses. The correlation between aortic LRP1 159 
expression, and AAA diameter was further assessed in leave-one-out sensitivity analyses. 160 
The association of plasma LRP1 with AAA presence was assessed via binary logistic 161 
regression corrected for confounders identified in univariate analyses. In vitro data comparing 162 
3 groups were assessed using one-way ANOVA applying Tukey’s post-hoc test for multiple 163 
comparisons. P values <0.05 were considered significant.  164 
 165 
Results 166 
Plasma LRP1 concentrations are not associated with AAA: LRP1 concentration was 167 
measured in plasma collected from 189 men with a small AAA, and 309 non-aneurysmal 168 
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controls (total n=498). Participant characteristics are shown in Table 1. Participants had 169 
similar age and history of dyslipidemia, diabetes and stroke. The prevalence of smoking, 170 
hypertension and CHD were significantly higher in men with AAA. No differences in plasma 171 
LRP1 concentration were observed between the groups Median plasma LRP1 concentration 172 
was 4.56 µg/mL (interquartile range [IQR] (3.39-5.96) for men that had AAA and 4.43 173 
µg/mL (IQR 3.44-5.84) for nonaneurysmal controls (p=0.48; Table 1, Fig 1A). Plasma LRP1 174 
concentrations did not correlate with IRA diameter when assessing the whole population 175 
(Spearman r=0.06, P=0.22; Figure 1B), or the experimental groups (for men with AAA: 176 
Spearman r=0.056, P=0.441; for controls: Spearman r=0.054, P=0.342, data not shown). 177 
 178 
Binary logistic regression was conducted to identify the major risk factors for AAA in the 179 
studied population. An increase in plasma LRP1 concentration of ~1 std dev (2.7 µg/mL) was 180 
not significantly associated with AAA presence in unadjusted analyses (odds ratio (OR): 1.07 181 
(95% CI: 0.89-1.28; P=0.476), or in analyses adjusting for waist to hip ratio, smoking history, 182 
hypertension and CHD (OR: 1.10 (95% CI: 0.91-1.32); P=0.35; (Supplementary Table 1). A 183 
history of ever having smoked (OR: 3.44 (95% CI: 2.12-5.58), P<0.001), and CHD (OR: 1.94 184 
(95% CI: 1.29-2.91), P<0.01) were independent risk factors for AAA in this population as 185 
previously described (Supplementary Table 1).19, 22  186 
 187 
Western blot analysis of aortic LRP1 expression: As plasma LRP1 concentrations were 188 
similar in AAA patients and controls, Western blotting experiments were conducted to verify 189 
whether IRA LRP1 expression was lower in AAA patients  compared to non-aneurysmal 190 
controls (n=6/group). Patients and controls were sex-matched (67% males/group, P=1.000). 191 
Younger AAA patients were specifically selected for this analysis to minimise age 192 
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imbalances between the groups although AAA patients were older than organ donors (median 193 
(IQR) age 58.0 (54.8-66.6) and 45.0 (34.0-51.0) years respectively; P=0.026). Median IRA 194 
diameter for the AAA patients was 65.8 (IQR: 57.3-79.2) mm. IRA measurements were not 195 
available for controls. Western blotting identified a band at ~90k Da in all samples which was 196 
selected for analysis as advised by the antibody manufacturer (Fig 2A and Supplementary 197 
Figure 1). Standardised median aortic LRP1 expression was ~3.4-fold lower in AAA patients 198 
than non-aneurysmal controls (median (inter-quartile range [IQR]) expression 1.72 (0.94-199 
3.14) and 5.91 (4.63-6.94) relative density units [RDU] respectively, P=0.004; Fig 2B). No 200 
significant correlation between standardised LRP1 expression and IRA diameter in the AAA 201 
patients was observed (Spearman r=0.600, P=0.242, Figure 2C). No significant correlation 202 
between tissue LRP1 expression and AAA diameter was observed following leave-one-out 203 
sensitivity analysis (Supplementary Table 2). 204 
 205 
In vitro LRP1 blockade inhibits VSMC MMP9 clearance: The relevance of LRP1 under-206 
expression to AAA pathology remains unclear. LRP1 dysfunction has been suggested to 207 
promote AAA through inefficient clearance of extracellular ligands including proteases.9 The 208 
effect of LRP1 blockade on extracellular clearance of MMP9 by VSMCs was assessed in 209 
vitro. VSMCs were exposed to LRP1 blocking antibodies, isotype control-IgG or vehicle for 210 
24 hours, prior to adding recombinant MMP9. Conditioned media MMP9 activity was 211 
assessed 24 and 48 hours after MMP9 addition using gelatin zymography (Supplementary 212 
Figure 2). 213 
 214 
After 24 hours, the MMP9 activity of culture supernatants was comparable between cells 215 
exposed to MMP9 with anti-LRP1 antibodies, isotype control IgG, or vehicle (mean (+ 216 
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standard error of the mean [SEM]) MMP9 activity: 3.69 (+0.50), 3.85 (+0.26) and 4.58 217 
(+0.31 RDU respectively; P=0.270; Figure 3A). The MMP9 activity of media from all 3 218 
groups was significantly greater than negative control cells which did not receive 219 
recombinant protease (all P values <0.05; data not shown). After 48 hours extracellular 220 
MMP9 activity differed significantly between VSMCs receiving anti-LRP1 antibodies, 221 
isotype control IgG, or vehicle (mean (+ SEM): 11.27 (+0.44), 8.29 (+0.45) and 9.80 (+0.75) 222 
RDU respectively; P=0.027; Figure 3B). Between-group comparisons demonstrated that 223 
conditioned media from VSMCs receiving LRP1-blocking antibodies exhibited significantly 224 
higher MMP9 activity than the control IgG1-exposed cells (mean difference between groups: 225 
2.97; 95% CI: 0.53-5.42; p<0.05). MMP9 activity from all 3 groups remained higher than the 226 
negative controls at this time point (all P-values <0.05; data not shown). 227 
228 
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Recent data suggest that the LRP1 rs1466535 polymorphism may be a specific AAA risk 230 
factor.7, 9, 10 A previous study has reported that LRP1 expression within the IRA is 231 
significantly lower in AAA patients compared to organ donor controls.17 We and others have 232 
demonstrated that proteins liberated from the aneurysm wall may enter the bloodstream and 233 
act as potential biomarkers for AAA.24-26 Consequently, we hypothesised that weak aortic 234 
LRP1 expression in AAA patients may increase circulating concentrations of this protein, 235 
although plasma LRP1 concentrations were similar in men with (n=189) and without AAA 236 
(n=309). Given this finding we attempted to verify the previous finding that LRP1 was 237 
downregulated within the aorta of AAA patients. We assessed LRP1 expression in IRA 238 
biopsies collected from AAA patients and organ donor controls. Currently, only one study 239 
has reported significant reductions in LRP1 expression in aortic biopsies collected from AAA 240 
patients compared to non-aneurysmal organ donor controls.17 Using antibodies against a 241 
different LRP1 immunogen and an alternative house-keeping protein, we confirm that aortic 242 
LRP1 protein expression was down-regulated in Australian patients with large AAAs 243 
compared to non-aneurysmal controls. Collectively, these findings suggest that LRP1 244 
dysregulation is localised to the aortic wall in AAA patients. This was assessed in vitro and 245 
our data suggest that LRP1 blockade significantly impairs the ability of VSMCs to remove 246 
the AAA relevant protease MMP9 from the surrounding media.  247 
 248 
Bown et al. suggested that the LRP1 rs1466535 CC genotype is associated with increased  249 
LRP1 expression (~1.2 fold) compared to the TT  genotype.7 It should be noted that Bown 250 
and colleagues analysed ascending aortic biopsies, compared to the IRA samples analysed in 251 
the current study and the previous investigation by Chan et al.17 Gene expression patterns 252 
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differ between aortic regions and work is needed to assess whether the rs1466535 CC 253 
genotype is associated with  differential IRA LRP1 expression.27 Thus, the mechanisms 254 
underpinning reduced IRA LRP1 expression in AAA patients remain unclear. Chan et al. 255 
hyothesised that LRP1 may be regulated by miR205.17 Kim and colleagues demonstrated that 256 
aortic expression of miR205 is significantly increased in apolipoprotein E deficient mice 257 
which developed AAA in response to angiotensin-II infusion.28 Moreover administration of 258 
anti-miR205 oligonucleotides to aortic endothelial cells greatly attenuated angiotensin-II 259 
induced AAA development. They also showed that LRP1 expression markedly decreased in 260 
response to angiotensin-II infusion, but was not rescued by in vivo anti-miR205 261 
administration, suggesting that miR205 may exert AAA-protective effects through other 262 
pathways.28 Recent data also demonstrate that normocholesterolaemic mice deficient in 263 
smooth muscle LRP1 (smLRP1-/-) are no more susceptible to angiotensin-II induced AAA 264 
than wild type controls, although the formation of large aneurysms within the ascending aorta 265 
and mesenteric artery was reported.29  It should be noted that normocholesterolaemic mice 266 
appear more resistant to angiotensin-II induced AAA than dyslipidaemic strains and future 267 
studies employing other AAA induction approaches in these mice are needed to further assess 268 
the role of LRP1 in AAA formation.23, 30, 31  269 
 270 
Although there is no direct evidence of a role for LRP1 in AAA formation, studies of the 271 
smLRP-/- mouse have demonstrated an important role for this protein in maintaining vascular 272 
integrity.14, 16, 32  smLRP-/- mice aortas show Marfan Syndrome-like phenotypes with 273 
disruption of the elastic laminae and VSMC hyperplasia, increased vessel tortuosity, 274 
thickness and dilatation.14-16, 32 Comparable circulating cholesterol concentrations in 275 
smLRP1-/- and control mice suggests that the observed pathologies are independent of 276 
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lipoprotein metabolism.14 Intriguingly, mice deficient in both smLRP1 and LDLR appear 277 
more susceptible to atherosclerosis than smLRP1+LDLR-/- controls demonstrated by 278 
widespread lesion formation following high cholesterol feeding.14, 16, 32 However, the 279 
aetiologies of AAA and atherothrombosis appear distinct.20, 33 AAA is associated with VSMC 280 
apoptosis and extracellular matrix degeneration, rather than cellular proliferation. MMP9, an 281 
LRP1 ligand, is over-expressed in human and mouse AAA biopsies, and is implicated in 282 
AAA pathogenesis.1, 31 The current study suggests a role for LRP1 in regulating aortic MMP9 283 
concentrations evidenced by heightened proteolytic activity in supernatants from LRP1 284 
compromised VSMCs. This is supported by prior data demonstrating increased MMP9 285 
activity in conditioned media harvested from mouse embryonic fibroblasts treated with an 286 
LRP1 antagonist, and an accumulation of MMP9 within the aortas of smLRP1-/- mice. 14, 34 287 
These findings suggest that aortic LRP1 dysregulation may exacerbate extracellular matrix 288 
proteolysis, although LRP1 has potential to contribute towards multiple AAA pathogenic 289 
mechanisms due to the broad spectrum of ligands for this receptor.9  290 
 291 
Extracellular forms of LRP1 are thought to result from shedding of the LRP1 ectodomain.35-37 292 
No association of circulating LRP1 concentration with AAA was observed suggesting that 293 
low IRA LRP1 expression in AAA patients does not result from heightened extracellular 294 
shedding. Immunohistochemistry data by Chan and colleagues demonstrate that LRP1 is 295 
predominantly expressed within the aortic media and adventitia, and confirm that this is 296 
reduced in human AAA although the cells which express LRP1 in the normal aorta were not 297 
investigated in this study. LRP1 is known to be expressed by VSMCs. Thus, it is possible that 298 
the loss of VSMCs typically demonstrated within the aortas of AAA patients may have 299 
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contributed to the down-regulation of LRP1 observed in the current study. 17 Further studies 300 
are required to directly assess this. 301 
 302 
There are several limitations to the current study. Firstly, the sample sizes employed in the 303 
Western blotting analyses were relatively small. As most AAAs are now managed by 304 
endovascular repair aortic wall biopsies can only be obtained from the occasional patient 305 
undergoing open surgery for a large AAA.1 Similarly, ethical and practical considerations 306 
prevent the collection of aortic biopsies from large numbers of control donors, however, 307 
sample sizes here are similar to other published studies.17, 22, 38-40 Secondly the organ donor 308 
controls were younger than the AAA patients and the possibility that the age imbalance may 309 
have contributed to differences in aortic LRP1 expression cannot be excluded. Limited 310 
clinical details were available for the organ donor controls and variation in cardiovascular 311 
risk factors between groups could not be adjusted for. However, organ donors are often the 312 
only viable source of healthy aortic biopsies.22, 41 Some previous studies have utilised 313 
macroscopically healthy tissues proximal to the AAA sac as matched control tissues, 314 
however these were not available for the current study.24, 38 A recent genome-wide expression 315 
study comparing biopsies from the proximal aneurysm neck with IRA biopsies from organ 316 
donors demonstrated significant reductions in LRP1 expression in the AAA patients.42  This 317 
suggests that LRP1 dysregulation precedes macroscopic AAA dilatation. Thirdly, no plasma 318 
samples were available from the AAA patients or organ donors who provided aortic biopsies. 319 
Thus, IRA and plasma LRP1 concentrations could not be directly compared in these 320 
individuals. Instead, plasma samples were obtained from men with screen-detected AAAs, 321 
not hospital referred patients. Consequently most aneurysmal blood donors had small (<50 322 
mm) AAAs. A difference in plasma LRP1 concentration may be seen when comparing 323 
patients with large AAAs to healthy controls, although this was not possible to assess in this 324 
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study. Furthermore, the ELISA we used recognises an extracellular LRP1 immunogen 325 
whereas the Western blotting antibody employed is raised against an intracellular epitope. 326 
This complicates direct comparison of the two tests. Limited sample availability prevented us 327 
from assessing aortic tissue extracts by ELISA to cross-validate the assay. Moreover it is 328 
possible that minor differences in plasma LRP1 concentration between the groups may have 329 
been masked by inter-assay variability (reported as <12%). Finally LRP1 genotype data were 330 
not available for any participants in this study. The rationale for assigning participants to 331 
experimental groups was therefore based on AAA.  332 
 333 
In summary, plasma LRP1 concentrations were similar in relatively large groups of 334 
community-dwelling men with and without AAA (n=189 and 309 respectively), minimising 335 
the biomarker potential for this molecule. Our data support an inverse association between 336 
IRA LRP1 expression and AAA presence, and suggest that LRP1 inhibition in VSMCs may 337 
potentially contribute to MMP9 accumulation within the aortic wall. Studies employing 338 
larger biopsy numbers and alternative methodologies such as RNA interference are required 339 
to validate these findings, and to further assess the impact of reduced LRP1 expression on 340 
AAA pathology. 341 
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Table 1: Clinical characteristics of 498 population screened men included in the plasma 478 
LRP1 analyses. 479 
Characteristic Men without AAA 
(AOD <30 mm; 
n=309) 
Men with AAA 
(AOD >30 mm 
n=189) 
P-value 
Infra-renal aortic diameter (mm) 19.5 (19.2-20.2) 33.7 (31.7-40.3) <0.001 
Age (years) 72 (68-75) 72 (68-75) 0.275 
Waist:hip ratio 0.95 (0.91-1.00) 0.96 (0.93-1.00) 0.069 
Plasma LRP1 (µg/mL) 4.43 (3.44-5.84) 4.56 (3.39-5.96) 0.476 
    
Past history of: 
Ever smoking 196 (63.4%) 163 (86.2%) <0.001 
Hypertension 126 (40.8%) 97 (51.3%) 0.022 
Dyslipidaemia 133 (43.0%) 90 (47.6%) 0.319 
Diabetes 34 (11.0%) 18 (9.5%) 0.600 
Stroke 19 (6.2%) 17 (9.0%) 0.234 
CHD 83 (26.9%) 83 (43.9%) <0.001 
 480 
CHD: Coronary heart disease. Nominal variables are presented as numbers and valid % and 481 
compared using the Chi-squared test. Continuous variables are presented as median and 482 
interquartile range and compared using the Mann-Whitney U test. 483 
484 
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Figure legends 485 
Figure 1: Plasma LRP1 is not associated with AAA presence. A) ELISA analysis revealed 486 
no difference in circulating LRP1 concentrations in men with AAA (n=189) and non-487 
aneurysmal controls (n=309, Mann-Whitney U test). B) No correlation was seen between 488 
plasma LRP1 concentration and infrarenal aortic diameter. Non-aneurysmal controls are 489 
boxed. 490 
 491 
Figure 2: Western blot analysis of LRP1 expression in infra-renal aortic biopsies recovered 492 
from AAA patients and non-aneurysmal organ donors. A) Immunoblot detailing relative 493 
infra-renal aortic LRP1 expression in AAA patients (AAA) and controls (CTRL). B) 494 
Comparisons between groups revealed standardised aortic LRP1 expression to be 495 
significantly lower in AAA patients than controls. Symbols represent individual samples, 496 
horizontal bars denote median and inter-quartile ranges. C) Standardised LRP1 expression 497 
did not significantly correlate with infra-renal aortic diameter in the AAA patients. 498 
 499 
Figure 3: The effect of in vitro LRP1 blockade on extracellular MMP9 activity. VSMCs 500 
were cultured in the presence of recombinant MMP9 after exposure to LRP1 blocking 501 
antibodies, control IgG1, or vehicle. MMP9 activity in cell culture supernatants was assessed 502 
24 (A) and 48 (B) hours after MMP9 addition via gelatin zymography. Cells which did not 503 
receive MMP9 are included as negative controls, but are not included in further analyses. 504 
Mean + SEM MMP9 activity are shown for each group (n=3 for all). MMP9 activity was 505 
assessed between experimental groups via one-way ANOVA, tables show mean differences 506 
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and 95% confidence intervals (CI) for comparisons between groups. NS: Non-significant, *: 507 
p<0.05 after correction via Tukey’s post-hoc test for multiple comparisons. 508 
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Supplementary File 1 – Detailed materials and methods. 
 
Supplemetary Table 1 – Independent risk factors for AAA in 498 community dwelling men 
screened for AAA. 
 
Supplementary Table 2 – Leave one out sensitivity analysis assessing the correlation 
between aortic LRP1 expression and AAA diameter. 
 
Supplementary Figure 1 – Raw Western blot images detailing IRA LRP1 and beta-actin 
expression in AAA patients and organ donor controls. 
 
Supplementary Figure 2 – Raw zymography gels showing MMP9 activity from in vitro 
VSMC culture experiments. 
SUPPLEMENTARY FILE 1 – DETAILED MATERIALS AND METHODS 
 
Participants: Samples collected from 3 Australian cohorts were used in different stages of the 
study as follows: 1) aortic biopsies from patients undergoing open surgery to repair AAA, 2) 
aortic biopsies from non-aneurysmal heart beating brain dead organ donors, and 3) plasma 
samples collected from participants of the Health In Men Study (HIMS).18 For patients 
undergoing AAA repair risk factors were recorded as previously described.19, 20 Briefly, 
characteristics collected for each patient included sex, age, history of hypertension, diabetes, 
coronary heart disease (CHD) and prescribed medications. Diabetes and hypertension were 
defined by a prior history of diagnosis or treatment of these conditions. Smoking status was 
defined as having ever or never smoked. CHD diagnosis was based on a history of angina, 
myocardial infarction or coronary artery revascularisation. Maximum infra-renal aortic 
diameter was measured from axial computed tomography angiography (CTA) images using 
the viewer function on a Philips workstation (MxView Visualization Workstation Software, 
Philips Electronics) and recorded in millimeters as previously reported.21 No clinical 
information other than age and sex was available for organ donor participants. The cohort 
characteristics and protocols of the HIMS have been previously described.18 HIMS was a 
community based screening program assessing AAA which used ultrasound to measure infra-
renal aortic diameter in Western Australian men aged >65 years. Maximum infra-renal aortic 
diameter of 30-55 mm was defined as a small AAA; and infrarenal aortic diameters >55 mm 
were considered large AAAs. Relevant to the current study, clinical information collected for 
each HIMS participant included age, medical history and smoking status. Anthropomorphic 
measurements including height, weight and hip and waist circumference were also recorded. 
Participants in the current study were selected based on blood sample availability, and 
completeness of clinical data. In all instances, appropriate written informed consent and 
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institutional ethics approval to use biological samples and clinical data for research purposes 
was provided.  
 
In vitro experiments: Commercial human aortic VSMC (CC-2571, Lonza) were maintained 
in growth medium (DMEM (DMEM/F12, Gibco) supplemented with 10% (v/v) heat-
inactivated foetal calf serum, 1% L-Glutamine and 1% penicillin/streptomycin, Gibco) in a 
humidified 5% CO2 atmosphere at 37oC. Cells were passaged when 70%–80% confluent. 
After 5 passages VSMCs were seeded into 12 well plates at a density of 1x106 cells/mL and 
allowed to adhere overnight.  LRP1 blocking antibodies or isotype control antibodies (#MA1-
27198 and MA5-14453, respectively, Thermo Fisher Scientific, Australia) were added to the 
culture media to final concentrations of 30µg/mL based on a previous publication using these 
antibodies in VSMCs.43 Cell culture supernatants were decanted after 24 hours and replaced 
with media containing recombinant human matrix metalloprotease 9 (MMP9, #911-MP-010, 
R and D Systems, USA), to a final concentration of 20ng/mL. This concentration was chosen 
as prior data have shown this is the approximate median plasma MMP9 concentration in 
patients with large stable AAAs,44 and was considered physiologically relevant. Cell culture 
supernatants were harvested at 24 and 48 hours, and stored at -80oC for later analysis. Data 
presented are from 3 independent culture experiments. 
 
Protein extraction and Western blotting: Isolation of aortic proteins and western blotting was 
performed as previously described.23 Full-thickness human abdominal aortic samples, or 
cultured VSMCs were homogenized in the presence of protease inhibitors to obtain protein 
extracts. Protein concentrations were determined using a Bradford protein assay kit (BioRad, 
USA). Samples (30 µg of protein per lane) were loaded onto a 10% SDS-polyacrylamide gel, 
electrophoresed (100 V, 90 min), and transferred (15 mA, 60 min) onto a polyvinylidene 
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difluoride membrane (BioRad, USA). The membrane <30 kDa was removed as mid-low 
molecular weight proteins were not targeted in this investigation. The remaining membrane 
was halved (cut at ~60 kDa) and each half separately blocked with 5% non-fat dry milk at 
4ºC overnight. The membrane containing the high molecular weight proteins (~60-250 kDa) 
was incubated with anti-LRP1 antibody (1:1000 dilution in PBSt [1 x PBS pH 7.4 + 1% (v/v) 
Tween 20], R&D Systems MAB6360, USA), proteins <60 kDa were incubated with anti-β 
actin antibody, 1:10,000 (Abcam, UK #AB75186). After 1 hour at room temperature, 
membranes were washed in TBSt (1 x TBS pH 7.4 + 1% (v/v) Tween 20, 3 x 10 mins) and 
incubated with anti-mouse HRP- (LRP1 blot), or anti-rabbit (β actin)- conjugated IgG 
(DakoCytomation, Denmark #P0447 and P0448 respectively) diluted 1:1,000 in PBSt for 1 
hour at room temperature. Membranes were washed (2 washes in TBSt, 1 wash in TBS for 10 
mins each). Protein expression was visualised with Western Lightning Chemiluminescence 
Reagent Plus (PerkinElmer Life Sciences, USA) and quantified using the Quantity One 
v4.6.7 software package (BioRad, USA). The relative density of the LRP1 band was 
standardised by dividing by mean beta-actin density for the respective experimental group. 
All presented Western blot data refer to standardised LRP1 expression. 
 
Gelatin zymography: Five µL of VSMC culture supernatant was loaded into each well of a 
10% polyacrylamide gel containing 1 mg/mL gelatin. Samples were electrophoresed as above 
and then washed in 2.5% (v/v) Triton X 100 for 15 minutes. After 2 washes, gels were 
incubated overnight in developing buffer (50mM Tris-HCl (pH 8.0), 5mM CaCl2) at 37oC 
prior to staining in 0.5% (w/v) Coomassie Blue R-250 for 30 mins. Gels were placed in 
destain solution (40% (v/v) methanol, 10% (v/v) acetic acid, 50% (v/v) water), to visualise 
areas of protease activity. Gels were analysed via densitometry as described above. 
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Measurement of plasma LRP1: Plasma LRP1 concentrations were measured using a 
commercially available ELISA according to the manufacturer’s directions (#E91010Hu, 
USCN Life Sciences, China). This ELISA employs antibodies raised against a soluble extra-
cellular LRP1 immunogen (ser4373-glu4409), suggesting suitability for plasma analysis. The 
manufacturer’s guidelines state that the minimum detectable concentration of human LRP1 
with this assay is 2.91 pg/mL and that no significant cross-reactivity with human LRP1 
analogues is reported. Reported inter and intra-assay variability are both <12%. Due to 
limited sample availability, single measurements were taken for each patient as previously 
described.19, 22  
 
Statistical analyses: Data were analysed using the SPSS v.21 statistical package (IBM). Plots 
were generated using Prism v6 software (GraphPad Software Inc, San Diego, USA). 
Continuous variables were compared between groups using the Mann-Whitney U test. 
Nominal variables were assessed using the chi-squared test. Correlation between variables 
was assessed using Spearman Rho analyses. The correlation between aortic LRP1 expression, 
and AAA diameter was further assessed in leave-one-out sensitivity analyses in which 
individual patients were systematically excluded. The association of plasma LRP1 with AAA 
presence was assessed via binary logistic regression corrected for waist:hip ratio and a history 
of ever smoking, hypertension or CHD based on significant, or near-significant differences 
between groups identified via univariate analysis. In vitro data comparing 3 groups were 
assessed using one-way ANOVA applying Tukey’s post-hoc test for multiple comparisons. 
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Supplementary Table 1: Independent risk factors for AAA in 498 community dwelling men 
screened for AAA. 
 
Characteristic Odds  ratio 95% CI P-value 
Unadjusted  
Plasma LRP1 concentration 1.07 0.89-1.28 0.476 
Adjusted for covariates 
Plasma LRP1 concentration 1.10 0.91-1.32 0.347 
Waist:hip ratio 1.16 0.96-1.40 0.133 
Ever smoking 3.44 2.12-5.58 <0.001 
Hypertension 1.33 0.89-1.98 0.160 
CHD 1.94 1.29-2.91 0.001 
 
CHD: Coronary heart disease. 
Odds ratios for plasma LRP1 concentration and waist:hip ratio refer to an increase of 
approximately 1 standard deviation (2.7 µg/ml and 0.06 respectively). For nominal 
characteristics, men with the risk factor were compared to those without. 
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Supplementary Table 2: Leave one out sensitivity analysis assessing the correlation 
between aortic LRP1 expression and AAA diameter. 
 
Patient excluded* AAA diameter (mm) LRP1 expression (RDU)† Spearman’s r P-value 
1 49.0 1.01 0.600 0.350 
2 60.0 1.78 0.700 0.233 
3 65.0 0.75 0.900 0.083 
4 60.5 1.67 0.700 0.233 
5 110.0 4.62 0.300 0.683 
6 68.9 2.65 0.300 0.683 
 
* Patient ID is arbitrary 
†
 Refers to LRP1 expression measured by Western blot (normalised to mean beta-actin 
expression for the whole group); RDU: Relative Density Units. 
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Supplementary Figure 2: Zymography gels showing MMP9 activity in conditioned media collected from VSMCs 24 and 48 hours after adding MMP9 to the 
culture. Details of reagents added to each culture are shown.  
 
 
